Puma Biotechnology Inc Common Stock
PBYIUnited States
5 filed reports · 245 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 950 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 710 | Dec 2025 |
Financial data
245 concepts · 1,660 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial237 concepts · 1,621 facts · Dec 2022 to Jun 2026
- CRO services16 · Dec 2024 to Jun 2026
- Other clinical development16 · Dec 2024 to Jun 2026
- Stockholders equity (US GAAP)16 · Dec 2022 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations15 · Dec 2022 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Costs and expenses12 · Dec 2023 to Jun 2026
- Current income tax expense benefit12 · Dec 2023 to Jun 2026
- Depreciation12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Operating lease expense12 · Dec 2023 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Provision for doubtful accounts12 · Dec 2023 to Jun 2026
- Research and development expense excluding acquired in process cost12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
Product1 concepts · 25 facts · Dec 2022 to Jun 2026
- Revenue25 · Dec 2022 to Jun 2026
Segment6 concepts · 12 facts · Jun 2025 to Jun 2026
- Cost of goods and services sold (US GAAP)2 · Jun 2025 to Jun 2026
- Costs and expenses2 · Jun 2025 to Jun 2026
- General and administrative expense (US GAAP)2 · Jun 2025 to Jun 2026
- Operating expenses (US GAAP)2 · Jun 2025 to Jun 2026
- Selling and marketing expense (US GAAP)2 · Jun 2025 to Jun 2026
- Share based compensation2 · Jun 2025 to Jun 2026
Geography1 concepts · 2 facts · Dec 2024 to Dec 2025
- Sublease income2 · Dec 2024 to Dec 2025
Segments
39 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service3 members · 25 facts
- Product12 · Dec 2023 to Jun 2026
- Royalty12 · Dec 2023 to Jun 2026
- Nerlynx1 · Dec 2022
Statement business segments1 member · 12 facts
- Development And Commercialization Of Innovative Products To Enhance Cancer Care12 · Jun 2025 to Jun 2026
Statement geographical1 member · 2 facts
- CA2 · Dec 2024 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
- FY2026 Q1May 8, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Nov 7, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.